AACR Annual Meeting 2018

NextGen Stars 

The NextGen Stars program provides an exciting opportunity to increase the visibility of early-career scientists at the AACR Annual Meeting and to support the professional development and advancement of those selected to speak. Eight outstanding NextGen Stars will present their work in major sessions at the AACR Annual Meeting 2018. Selections were made through a competitive application process that was limited to AACR Associate Members and AACR Active Members who were at the junior faculty level (not higher than assistant professor or equivalent).

Congratulations to the 2018 NextGen Stars!

Samuel F. Bakhoum, MD, PhD
Holman Research Fellow, Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York
Chromosomal instability promotes metastasis through a cytosolic DNA response

Major Symposium
Tumor-Host Interactions Regulating Cancer Metastasis
Tuesday, April 17, 2018, 1-2:45 p.m.
Room W190 – McCormick Place West (Level 1)

Stacey D. Finley, PhD
Assistant Professor, Department of Biomedical Engineering
University of Southern California, Los Angeles, California
Effects of altering receptor structure in CAR T cells: Predictions from an experimentally-validated systems biology model

Major Symposium
Translational Applications of Systems Biology
Sunday, April 15, 2018, 1-2:45 p.m.
Room S406 (Vista Ballroom) – McCormick Place South (Level 4)

Michael E. Fraser, PhD
Director, Prostate Cancer Research
Ontario Institute for Cancer Research, Toronto, Ontario, Canada
The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience

Recent Advances in Prevention and Interception Research
Precision Prevention and Early Detection of Cancer
Wednesday, April 18, 2018, 10:10 a.m.-12:10 p.m.
Room W190 – McCormick Place West (Level 1)

Yejing Ge, PhD
Postdoctoral Fellow, Laboratory of Mammalian Cell Biology & Development
The Rockefeller University, New York, New York
Functional interrogation of cell plasticity in cancer

Major Symposium
Genetics and Epigenetics in Tumor and TME: Origins, Evolution and Drug Resistance
Tuesday, April 17, 2018, 1-2:45 p.m.
Room W196 – McCormick Place West (Level 1)

Willy Hugo, PhD
Adjunct Assistant Professor
University of California Los Angeles, Los Angeles, California
Immune Evasion mechanisms in melanoma resistant to targeted- and/or immunotherapy

Major Symposium
Genomic/Functional Screens to Predict Response/Resistance to Immunotherapy
Tuesday, April 17, 2018, 1-2:45 p.m.
N Hall B (Plenary Hall) – McCormick Place North (Level 3)

Ciara Metcalfe, PhD
Scientist, Translational Oncology
Genentech, South San Francisco, California
Not all “SERDs” are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics

Major Symposium
Optimizing Response to Endocrine Therapy
Tuesday, April 17, 2018, 1-2:45 p.m.
Room N427 – McCormick Place North (Level 4)

Richard L. Possemato, PhD
Assistant Professor, Pathology
NYU School of Medicine, New York, New York
NFS1 undergoes positive selection in lung tumors and protects cells from ferroptosis

Recent Advances in Diagnostics and Therapeutics Research
Metabolic Vulnerabilities and Cancer Therapy
Monday, April 16, 2018, 1-2:45 p.m.
Room S100 (Grand Ballroom) – McCormick Place South (Level 1)

A. Hunter Shain, PhD
Assistant Professor, Dermatology
University of California San Francisco, San Francisco, California
Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution

Recent Advances in Diagnostics and Therapeutics Research
Recent Advances of Single-Cell Genomics in Cancer Research
Wednesday, April 18, 2018, 10:15 a.m.-12 p.m.

View the abstracts of the NextGen Stars' presentations from the AACR Annual Meeting 2017:

Valsamo Anagnostou, Johns Hopkins Kimmel Comprehensive  Cancer Center, Baltimore, Maryland
Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer

Major Symposium
Mechanisms Regulating Immune Checkpoint Therapies
Monday, April 3, 2017, 10:30 a.m.-12:15 p.m.
Room 146, Level 1, Washington Convention Center

Bishoy Faltas, Weill Cornell Medical College, New York, New York
Genomic dissection of the clonal evolution dynamics of chemotherapy-resistant urothelial carcinoma

Recent Advances in Organ Site Research
Bladder Cancer
Wednesday, April 5, 2017, 10:15 a.m.-12:00 p.m.
Room 151, Level 1, Washington Convention Center

Amanda Lund, Oregon Health & Science University, Portland, Oregon
Lymphatic vessels: Balancing immune priming and immune evasion in melanoma

Major Symposium
The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance
Monday, April 3, 2017, 10:30 a.m.-12:15 p.m.
Room 202, Level 2, Washington Convention Center

Nardin Samuel, University of Toronto, Toronto, Ontario, Canada
TP53-mediated human cancer susceptibility is defined by epigenetic dysregulation of microRNA-34A

Major Symposium
Dysregulation of MicroRNAs Leads to Target Therapy
Tuesday, April 4, 2016, 1:00 p.m.-2:45 p.m.
Room 152, Level 1, Washington Convention Center

Mingyang Song, Massachusetts General Hospital, Boston, Massachusetts
Marine Omega-3 polyunsaturated fatty acid and colorectal cancer prevention and treatment

Recent Advances in Prevention Research
Diet and Precision Medicine in Cancer Prevention: The Role of Genetic Background, the Microbiome, and Epigenetic Mechanisms
Monday, April 3, 2017, 10:30 a.m.-12:15 p.m.
Room 145, Level 1, Washington Convention Center

Jesse Zaretsky, University of California, Los Angeles, California
Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations

Major Symposium
Mechanisms of Primary and Acquired Resistance to Immunotherapy
Tuesday, April 4, 2017, 10:30 a.m.-12:15 p.m.
Hall D-E, Level 2, Washington Convention Center